Allogene Therapeutics(ALLO.US)

Last Updated 19:00:00 ET
longbridge loading

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

Tip Ranks·
US
ALLO
-0.26%
US
XBI
+2.46%
US
FBT
+0.60%
Tip Ranks·
US
ALLO
-0.26%
US
XBI
+2.46%
US
FBT
+0.60%

Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity

TradingView·
US
ALLO
-0.26%
US
SBIO
+2.20%
US
IBB
+1.41%
TradingView·
US
ALLO
-0.26%
US
SBIO
+2.20%
US
IBB
+1.41%

Allogene Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
ALLO
-0.26%
Earnings Watch·
US
ALLO
-0.26%

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Unusual Whales·
US
ALLO
-0.26%
US
LABU
+7.09%
US
XBI
+2.46%
Unusual Whales·
US
ALLO
-0.26%
US
LABU
+7.09%
US
XBI
+2.46%

Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology

Unusual Whales·
US
ALLO
-0.26%
US
MBX
+0.33%
US
DTIL
+3.77%
Unusual Whales·
US
ALLO
-0.26%
US
MBX
+0.33%
US
DTIL
+3.77%
© 2026 Longbridge｜Disclaimer